|
May 2
|
AstraZeneca (LSE:AZN) Announces Positive Results From Breztri Trials For Uncontrolled Asthma
|
|
May 2
|
Here's what top C-suites are saying about tariffs
|
|
May 2
|
European Equities Close Sharply Higher in Friday Trading; Eurozone Inflation Unchanged at 2.2%
|
|
May 2
|
AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma
|
|
May 2
|
Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time.
|
|
May 2
|
Amgen's Q1 Earnings Beat Estimates, Key Drugs Drive Sales Growth
|
|
May 2
|
AstraZeneca’s triple-combo triumphs in two Phase III asthma trials
|
|
May 2
|
Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma
|
|
May 2
|
BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma
|
|
May 1
|
'Declare victory and move on': Eli Lilly CEO on Trump tariff threat
|
|
May 1
|
Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View
|
|
May 1
|
AstraZeneca quietly exits neuroscience
|
|
May 1
|
3 UK Stocks Estimated To Be 21.1% To 46.6% Below Intrinsic Value
|
|
Apr 30
|
Imfinzi approval positions AstraZeneca at forefront of perioperative MIBC
|
|
Apr 30
|
AstraZeneca’s Truqap fails in another Phase III trial
|
|
Apr 30
|
AstraZeneca PLC (AZN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ...
|
|
Apr 29
|
AstraZeneca Tops Earnings Views And Shares Rise Despite Cancer Miss
|
|
Apr 29
|
Sector Update: Health Care Stocks Gain Late Afternoon
|
|
Apr 29
|
AstraZeneca CEO calls for increased European investment in pharma
|
|
Apr 25
|
The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS
|